Didžioji Britanija - anglų - MHRA (Medicines & Healthcare Products Regulatory Agency)

vifor pharma uk ltd - patiromer sorbitex calcium - powder - 8.4gram

Europos Sąjunga - anglų - EMA (European Medicines Agency)

vifor fresenius medical care renal pharma france - sucroferric oxyhydroxide - hyperphosphatemia; renal dialysis - drugs for treatment of hyperkalemia and hyperphosphatemia - velphoro is indicated for the control of serum phosphorus levels in adult chronic kidney disease (ckd) patients on haemodialysis (hd) or peritoneal dialysis (pd).velphoro is indicated for the control of serum phosphorus levels in paediatric patients 2 years of age and older with ckd stages 4-5 (defined by a glomerular filtration rate

Australija - anglų - Department of Health (Therapeutic Goods Administration)

vifor pharma pty ltd - iron polymaltose -

Australija - anglų - Department of Health (Therapeutic Goods Administration)

vifor pharma pty ltd - ulipristal acetate -

Jungtiniai Arabų Emyratai - anglų - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

pharmatrade france - 3 glass vials (1 ml) - injection - 50 micrograms/ml - nervous system-n/a

Jungtiniai Arabų Emyratai - anglų - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

pharmatrade france - 180’s hdpe bottle with crc - capsule - 10 mg/capsule - malignant disease , immumosuppression-immunosuppressants

Singapūras - anglų - HSA (Health Sciences Authority)

vifor pharma asia pacific pte. ltd. - ferric carboxymaltose 180 mg eqv iron - injection, solution - 50mg - ferric carboxymaltose 180 mg eqv iron 50 mg/ml

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

vifor (international) inc. - epoetin (unii: 64fs3bfh5w) (epoetin - unii:64fs3bfh5w) - retacrit is indicated for the treatment of anemia due to chronic kidney disease (ckd), including patients on dialysis and not on dialysis to decrease the need for red blood cell (rbc) transfusion. retacrit is indicated for the treatment of anemia due to zidovudine administered at ≤ 4,200 mg/week in patients with hiv-infection with endogenous serum erythropoietin levels of ≤ 500 munits/ml. retacrit is indicated for the treatment of anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy. retacrit is indicated to reduce the need for allogeneic rbc transfusions among patients with perioperative hemoglobin > 10 to ≤ 13 g/dl who are at high risk for perioperative blood loss from elective, noncardiac, nonvascular surgery. retacrit is not indicated for patients who are willing to donate autologous blood pre-operatively. retacrit has not been shown to improv

Europos Sąjunga - anglų - EMA (European Medicines Agency)

vifor fresenius medical care renal pharma france - patiromer sorbitex calcium - hyperkalemia - drugs for treatment of hyperkalemia and hyperphosphatemia - veltassa is indicated for the treatment of hyperkalaemia in adults.

Europos Sąjunga - anglų - EMA (European Medicines Agency)

vifor fresenius medical care renal pharma france - avacopan - microscopic polyangiitis; wegener granulomatosis - immunosuppressants - tavneos, in combination with a rituximab or cyclophosphamide regimen, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (gpa) or microscopic polyangiitis (mpa).